Type 1 Diabetes New Study – Adding Ozempic, a once-weekly injection
Please fill in your details
About the Study
This study is for patients with Type 1 Diabetes, using an insulin pump, and currently have obesity. Participants will add either semgalutide (Ozempic) or a placebo to their current treatment. Ozempic is a once-weekly injection approved for Type 2 Diabetes and can help with weight loss.
The goal of the study is to see if adding Ozempic can help patients with Type 1 Diabetes lose body weight and improve blood sugar control.
All participants enrolled in this study will receive study meds at no charge and will be compensated for their time and travel.
Participant Eligibility Criteria ( To take part in the study )
- Type 1 Diabetes
- Have obesity
- Using an insulin pump
- A1C between 7 and 10%
- Age between 19 to 59 only